We are live on ! Find out more
ZVRA icon

Zevra Therapeutics

121 hedge funds and large institutions have $319M invested in Zevra Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 45 increasing their positions, 29 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 14

55% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 29

25% more capital inflows, than outflows

Capital inflows: $37.8M | Capital outflows: $30.1M

9% more funds holding

Funds holding: 111 → 121 (+10)

0.64% more ownership

Funds ownership: 65.56% → 66.2% (+0.64%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

14% less call options, than puts

Call options by funds: $5.02M | Put options by funds: $5.81M

Holders
121
Holders Change
+10
Holders Change %
+9.01%
% of All Funds
1.59%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
24
Increased
45
Reduced
29
Closed
14
Calls
$5.02​M
Puts
$5.81​M
Net Calls
-⁠$793​K
Net Calls Change
+$1.51​M

ZVRA Hedge Fund Activity: Q2 2025 in Review

121 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2025, worth a combined $319M — up 17% from $272M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ZVRA positions and 14 closed out — a net gain of 10 holders — while 45 added to existing stakes and 29 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $6.01M. The largest seller was Readystate Asset Management, cutting an estimated $4.64M.

  • 121 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2025, up from 111 in Q1 2025.
  • Funds reported $319M of Zevra Therapeutics stock for Q2 2025, up 17% quarter-over-quarter.
  • 24 funds opened new Zevra Therapeutics positions in Q2 2025 and 14 closed out, a net change of +10 holders.
  • The largest Zevra Therapeutics buyer in Q2 2025 was Rubric Capital Management (New York), an estimated $6.01M added.
  • The largest Zevra Therapeutics seller in Q2 2025 was Readystate Asset Management, an estimated $4.64M sold.

Based on aggregated 13F filings for Q2 2025.